Bristol Myers and Janssen race toward PhIII with a next-gen blood thinner
Bristol Myers Squibb and J&J joined forces three years ago with a vision: They wanted to create a blood thinner with the efficacy of their current drugs Eliquis and Xarelto, but without the heightened risk of bleeding.
On Monday, they announced they’re well on their way with a Factor XIa inhibitor called milvexian.
Milvexian, also known as BMS-986177, significantly lowered patients’ rate of venous thromboembolism (VTE) after knee surgery compared to the commonly used anticoagulant enoxaparin in a Phase II study, the partners said at this year’s American Heart Association conference — and without increasing risk of bleeding.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.